Home Regulatory Zydus Pharmaceuticals (USA) Inc gets final US FDA approval to market Roflumilast tablets

Zydus Pharmaceuticals (USA) Inc gets final US FDA approval to market Roflumilast tablets

by admin
0 comment
ZydusCadila, Pharmaceuticals, Commercialisation, Medicines, US, Market, Generic, Drug, Marketing, Import, Firm

Summary:

Zydus, being one of the first applicants for Roflumilast Tablets, 500 mcg, is eligible for 180 days of shared generic drug exclusivity, Cadlia Healthcare said in a regulatory filing.

Cadlia Healthcare Ltd on Monday said group firm Zydus Pharmaceuticals (USA) Inc has received final approval from the US health regulator to market its generic version of Roflumilast tablets in the strength of 500 mcg indicated to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations.

Zydus, being one of the first applicants for Roflumilast Tablets, 500 mcg, is eligible for 180 days of shared generic drug exclusivity, Cadlia Healthcare said in a regulatory filing.

ZydusCadila, Pharmaceuticals, Commercialisation, Medicines, US, Market, Generic, Drug, Marketing, Import, Firm

The US Food and Drug Administration (USFDA) has also given a tentative approval for Roflumilast tablets, 250 mcg 

The US Food and Drug Administration (USFDA) has also given a tentative approval for Roflumilast tablets, 250 mcg, the company added. The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.

Roflumilast tablets are indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations, it added.

The group now has 327 approvals and has so far filed over 400 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04.

Roflumilast

Roflumilast, sold under the trade name Daxas among others, is a drug that acts as a selective, long-acting inhibitor of the enzyme phosphodiesterase-4.Roflumilast is in a class of medications called phosphodiesterase inhibitors. It works by decreasing swelling in the lungs.

INDICATION. Roflumilast is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. This medication is not a bronchodilator, and it is not indicated for the treatment of acute bronchospasm.

 

For more Information: Sign in Websites for Agrochemical & Pharmaceutical Databases:

Website : https://www.chemrobotics.com/ (Agrochemical Databases)

Website : https://chemroboticspharma.com/  (Pharmaceutical Databases)

 

 

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Our Company

ChemRobotics is a global Scientific, Technical & Business data intelligence company, especially in the field of Pharmaceutical, Agrochemical, Veterinary and Fine Chemical.

ChemRobotics Times

Subscribe ChemRobotics for the latest updates in the Pharmaceutical, Agrochemical, Veterinary, and Fine Chemical Industries

Laest News

ChemRobotics Pvt. Ltd. © 2023, All Rights Reserved. 

Designed and Developed by Ample eBusiness